positive
India’s Pharma Exports Near $30 Billion as CRDMO Sector Gains Traction
A report by EY Parthenon and Organisation of Pharmaceutical Producers of India (OPPI) reveals that India’s pharmaceutical exports are approaching USD 30 billion, driven by growth in CRDMO (Contract Research, Development & Manufacturing Organisations) and Global Capability Centres (GCCs).
The transition from generic manufacturing to higher-value innovation is underway, supported by digital-first strategies and policy reforms. The report highlights that regulatory agility and talent development will be crucial as India aspires to become a global life-sciences innovation hub.
Tags:
- india
- pharma
Ey• By Harsh Ranjan
Explore:High Return Equity Mutual Fund
positive
India’s Pharma Exports Near $30 Billion as CRDMO Sector Gains Traction
A report by EY Parthenon and Organisation of Pharmaceutical Producers of India (OPPI) reveals that India’s pharmaceutical exports are approaching USD 30 billion, driven by growth in CRDMO (Contract Research, Development & Manufacturing Organisations) and Global Capability Centres (GCCs).
The transition from generic manufacturing to higher-value innovation is underway, supported by digital-first strategies and policy reforms. The report highlights that regulatory agility and talent development will be crucial as India aspires to become a global life-sciences innovation hub.
Tags:
- india
- pharma
Ey• By Harsh Ranjan
Explore:High Return Equity Mutual Fund
1 min read
77 words
India’s pharma exports near USD 30 bn as CRDMO/GCC segments expand, according to EY-OPPI report.
A report by EY Parthenon and Organisation of Pharmaceutical Producers of India (OPPI) reveals that India’s pharmaceutical exports are approaching USD 30 billion, driven by growth in CRDMO (Contract Research, Development & Manufacturing Organisations) and Global Capability Centres (GCCs).
The transition from generic manufacturing to higher-value innovation is underway, supported by digital-first strategies and policy reforms. The report highlights that regulatory agility and talent development will be crucial as India aspires to become a global life-sciences innovation hub.
A report by EY Parthenon and Organisation of Pharmaceutical Producers of India (OPPI) reveals that India’s pharmaceutical exports are approaching USD 30 billion, driven by growth in CRDMO (Contract Research, Development & Manufacturing Organisations) and Global Capability Centres (GCCs).
The transition from generic manufacturing to higher-value innovation is underway, supported by digital-first strategies and policy reforms. The report highlights that regulatory agility and talent development will be crucial as India aspires to become a global life-sciences innovation hub.
Tags:
- india
- pharma
- india
- pharma
- exports
- innovation
- healthcare